Back to dashboard
CommercialPrior AuthMedium impact

08.01.13l, Brentuximab Vedotin (Adcetris®)

Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Oct 20, 2025
We identified it
Jun 19, 2026
Days to comply
—

Summary

IBX has updated their medical policy for Brentuximab Vedotin (Adcetris®), a specialty pharmacy drug, with changes to medical necessity criteria, coding requirements, and general guidelines. This affects commercial plan members requiring this oncology medication.

Action Required

Action needed
By October 20, 2025: Review updated IBX policy 08.01.13l for Brentuximab Vedotin (Adcetris®) at the source URL. Update prior authorization procedures and medical necessity documentation requirements for commercial plans. Ensure coding staff are aware of any new coding guidelines for this specialty oncology drug.

Related policy hubs